Paper36068002
Intralesional collagenase Clostridium histolyticum vs. verapamil injections in males with Peyronie's Disease: A prospective, matched-pair, non-blinded, randomised clinical study comparing clinical outcomes and patient satisfaction rates.
Chung E and 1 other. Investig Clin Urol, 2022. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Intralesional collagenase Clostridium histolyticum vs. verapamil injections in males with Peyronie's Disease: A prospective, matched-pair, non-blinded, randomised clinical study comparing clinical outcomes and patient satisfaction rates. Papers, record 36068002. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36068002
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Intralesional collagenase Clostridium histolyticum vs. verapamil injections in males with Peyronie's Disease: A prospective, matched-pair, non-blinded, randomised clinical study comparing clinical outcomes and patient satisfaction rates.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Microbial Collagenase | Major topic |
| Penile Induration | Major topic |
| Humans | |
| Injections, Intralesional | |
| Male | |
| Patient Satisfaction | |
| Penis | |
| Prospective Studies | |
| Treatment Outcome | |
| Verapamil |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 37133744 | Male and Female Sexual Function and Dysfunction; Andrology. | https://conductscience.org/library/papers/37133744 |
Source PubMed
References24
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30956106 | Efficacy of Combined Collagenase Clostridium histolyticum and RestoreX Penile Traction Therapy in Men with Peyronie's Disease. | J Sex Med | 2019 | https://conductscience.org/library/papers/30956106 | PubMed |
| 2 | 23376148 | Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. | J Urol | 2013 | https://conductscience.org/library/papers/23376148 | PubMed |
| 3 | 28923562 | Intralesional Injection of Collagenase Clostridium histolyticum May Increase the Risk of Late-Onset Penile Fracture. | Sex Med Rev | 2018 | https://conductscience.org/library/papers/28923562 | PubMed |
| 4 | 32542884 | A clinical pathway for the management of Peyronie's disease: integrating clinical guidelines from the International Society of Sexual Medicine, American Urological Association and European Urological Association. | BJU Int | 2020 | https://conductscience.org/library/papers/32542884 | PubMed |
| 5 | 25818264 | Analysis of the clinical safety of intralesional injection of collagenase Clostridium histolyticum (CCH) for adults with Peyronie's disease (PD). | BJU Int | 2015 | https://conductscience.org/library/papers/25818264 | PubMed |
| 6 | 17482941 | Open preliminary randomized prospective clinical trial of efficacy and safety of three different verapamil dilutions for intraplaque therapy of Peyronie's disease. | Urology | 2007 | https://conductscience.org/library/papers/17482941 | PubMed |
| 7 | 28454897 | Collagenase Clostridium Histolyticum in the Treatment of Urologic Disease: Current and Future Impact. | Sex Med Rev | 2018 | https://conductscience.org/library/papers/28454897 | PubMed |
| 8 | 19199072 | Effect of intralesional verapamil for treatment of Peyronie's disease: a randomized single-blind, placebo-controlled study. | Int Urol Nephrol | 2009 | https://conductscience.org/library/papers/19199072 | PubMed |
| 9 | 28612401 | Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol. | BJU Int | 2017 | https://conductscience.org/library/papers/28612401 | PubMed |
| 10 | 23174244 | A comparative study of the efficacy of intralesional verapamil versus normal saline injection in a novel Peyronie disease animal model: assessment of immunohistopathological changes and erectile function outcome. | J Urol | 2013 | https://conductscience.org/library/papers/23174244 | PubMed |
| 11 | 26066402 | Peyronie's Disease: AUA Guideline. | J Urol | 2015 | https://conductscience.org/library/papers/26066402 | PubMed |
| 12 | 28502596 | Safety Profile of Collagenase Clostridium Histolyticum Stratified by Degree of Penile Curvature in Patients With Peyronie Disease. | Urology | 2017 | https://conductscience.org/library/papers/28502596 | PubMed |
| 13 | 29733116 | Collagenase clostridium histolyticum for the treatment of Peyronie's disease: a prospective Italian multicentric study. | Andrology | 2018 | https://conductscience.org/library/papers/29733116 | PubMed |
| 14 | 20666587 | Collagenase clostridium histolyticum for Dupuytren's contracture. | Expert Opin Biol Ther | 2010 | https://conductscience.org/library/papers/20666587 | PubMed |
| 15 | 31475740 | A snapshot of intralesional verapamil injection in the treatment of Peyronie's disease today. | Andrologia | 2019 | https://conductscience.org/library/papers/31475740 | PubMed |
| 16 | 30245025 | Sildenafil 25 mg ODT + Collagenase Clostridium hystoliticum vs Collagenase Clostridium hystoliticum Alone for the Management of Peyronie's Disease: A Matched-Pair Comparison Analysis. | J Sex Med | 2018 | https://conductscience.org/library/papers/30245025 | PubMed |
| 17 | 27215686 | Evidence-Based Management Guidelines on Peyronie's Disease. | J Sex Med | 2016 | https://conductscience.org/library/papers/27215686 | PubMed |
| 18 | 27045265 | Results of SMSNA Survey Regarding Complications Following Intralesional Injection Therapy With Collagenase Clostridium Histolyticum for Peyronie's Disease. | J Sex Med | 2016 | https://conductscience.org/library/papers/27045265 | PubMed |
| 19 | 23421851 | Peyronie's disease and mechanotransduction: an in vitro analysis of the cellular changes to Peyronie's disease in a cell-culture strain system. | J Sex Med | 2013 | https://conductscience.org/library/papers/23421851 | PubMed |
| 20 | 32345061 | A state-of-art review on collagenase Clostridium Histolyticum and Peyronie's disease: drug profile, clinical evidence and safety outcomes. | Expert Opin Biol Ther | 2020 | https://conductscience.org/library/papers/32345061 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| ELN | 2006 | PubTator's text mining | https://conductscience.org/library/genes/2006 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36068002
GET https://conductscience.org/api/papers/v1/36068002/references?page=2